Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.

GL, Goll; KK, Jørgensen; J, Sexton; IC, Olsen; N, Bolstad; EA, Haavardsholm; KEA, Lundin; KS, Tveit; M, Lorentzen; IP, Berset; BTS, Fevang; S, Kalstad; K, Ryggen; DJ, Warren; RA, Klaasen; Ø, Asak; S, Baigh; IM, Blomgren; Ø, Brenna; TJ, Bruun; K, Dvergsnes; SO, Frigstad; IM, Hansen; ISH, Hatten; G, Huppertz-Hauss; M, Henriksen; SS, Hoie; J, Krogh; IP, Midtgard; P, Mielnik; B, Moum; G, Noraberg; A, Poyan; U, Prestegård; HU, Rashid; EK, Strand; K, Skjetne; KA, Seeberg; R, Torp; CM, Ystrøm; C, Vold; CC, Zettel; K, Waksvik; B, Gulbrandsen; J, Hagfors; C, Mørk; J, Jahnsen; TK, Kvien

doi:10.1111/joim.12880

Public

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.

Shared by NobleBlocks on Apr 12, 2019 • 12:00 AM UTC

Authors:

Goll GL

Jørgensen KK

Sexton J

Abstract

<h4>Background and objectives</h4>The 52-week, randomized, double-blind, noninferiority, government-funded NOR-SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT-P13 was not inferior to continued treatment with infliximab originator. The NOR-SWITCH ex...

Subject

Health Economics

Infliximab

Drug Costs

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!